Key result
Development of microalbuminuria during antihypertensive treatment significantly increased the risk of cardiovascular events compared to remaining normoalbuminuric (18% vs 8%; HR 1.60; 95% CI 1.04-2.46).
Why the study?
Does the development or persistence of microalbuminuria predict fatal and nonfatal cardiovascular events in hypertensive patients without previous cardiovascular disease?
Cohort (n=2,835)
Does the development or persistence of microalbuminuria predict fatal and nonfatal cardiovascular events in hypertensive patients without previous cardiovascular disease?
Hazard Ratio: 1.6 (95% CI 1.04–2.46)
Absolute Event Rate: 18% vs 8%
p-value: p=<0.001
Development or persistence of microalbuminuria during antihypertensive treatment is an independent predictor of cardiovascular events in patients with essential hypertension.
No takes yet. Share an insight, caveat, or question.
May warrant closer monitoring in treated hypertension; hypothesis-generating for trials targeting albuminuria reduction.
Pascual et al. (2014) conducted a cohort in Essential Hypertension (n=2,835). Development of microalbuminuria vs. Remaining normoalbuminuric was evaluated on Incidence of fatal and first nonfatal cardiovascular events (HR 1.60, 95% CI 1.04-2.46, p=<0.001). Development of microalbuminuria during antihypertensive treatment significantly increased the risk of cardiovascular events compared to remaining normoalbuminuric (18% vs 8%; HR 1.60; 95% CI 1.04-2.46).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: